Loading...
Back to narrative

INDGN: Upcoming Board Meeting Will Drive Continued Positive Momentum

Digital Transformation And AI Adoption Will Expand Pharma Market

INDGN logo
INDGN
AnalystConsensusTarget
Not Invested
Published 11 May 2025

Update shared on 09 Dec 2025

Fair value Increased 0.70%
Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-11.7%
7D
0.7%

Analysts have modestly raised their price target on Indegene by about 1 percent to approximately $612, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite largely stable profit margin and discount rate assumptions.

What's in the News

  • Board meeting scheduled on October 30, 2025 to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025 and consider equity allotments under ESOP 2020 and RSU 2020 schemes (company filing)
  • Expansion of Indegene's Consulting Practice to provide integrated strategy and transformation support for life sciences clients facing large scale, technology driven change across the value chain (company announcement)
  • Strategic partnership with Datavant to integrate its health data network into Indegene's NEXT Patient Recruitment platform, aiming to speed up clinical trial enrollment and improve patient recruitment, particularly in rare diseases (Datavant and company announcement)

Valuation Changes

  • The fair value estimate has risen slightly to about ₹612 per share from roughly ₹608 per share, reflecting a modest upward revision.
  • The discount rate has edged down marginally to about 14.01 percent from 14.04 percent, indicating a slightly lower implied risk profile.
  • Revenue growth has increased slightly to around 16.97 percent from 16.90 percent, signaling a modestly stronger long term growth outlook.
  • The net profit margin has dipped marginally to about 13.16 percent from 13.18 percent, suggesting essentially stable long run profitability assumptions.
  • The future P/E has risen slightly to around 34.16x from 33.94x, implying a small expansion in the expected valuation multiple.

Have other thoughts on Indegene?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.